About
IMAGENDO® is a pioneering medical AI research initiative based in Australia, focused on revolutionizing the diagnosis of endometriosis — a condition that historically suffers from significant diagnostic delays due to its reliance on surgical confirmation. The study harnesses artificial intelligence to interpret non-invasive medical imaging, specifically pelvic magnetic resonance imaging (MRI) and transvaginal ultrasound scans (TVUS), to detect endometriosis accurately and early. The research is structured across multiple stages: Stage One involves participants who have previously undergone pelvic MRI or TVUS scans, while Stage Three targets individuals planning pelvic surgery within six months to investigate pelvic pain or suspected endometriosis. The study actively recruits females aged 18–45 and is led by leading researchers including Professor Louise Hull. Funded by the Australian Government, Endometriosis Australia, the Australasian Society for Ultrasound in Medicine, the Australian Gynaecological Endoscopy Association, and the Lions Club, IMAGENDO® represents a significant intersection of clinical research, medical imaging, and AI-driven diagnostics. Its goal is to provide a reliable, non-invasive alternative to laparoscopic surgery for endometriosis diagnosis — reducing patient burden, healthcare costs, and years-long diagnostic delays. This tool is primarily aimed at medical researchers, clinicians, and study participants contributing to the advancement of women's health diagnostics.
Key Features
- AI-Driven Medical Image Analysis: Uses artificial intelligence to analyze pelvic MRI and transvaginal ultrasound scans for accurate, non-invasive endometriosis detection.
- Multi-Stage Research Study: Structured into multiple study stages targeting different participant profiles, from those with prior scans to those planning pelvic surgery.
- Non-Invasive Diagnostic Approach: Aims to eliminate the need for laparoscopic surgery as the primary means of confirming an endometriosis diagnosis.
- Participant-Centered Design: Actively recruits females aged 18–45 across Australia to contribute imaging data that trains and validates the AI diagnostic model.
- Government and Institutional Funding: Backed by the Australian Government, Endometriosis Australia, and major medical societies, ensuring rigorous scientific standards.
Use Cases
- Medical researchers studying non-invasive diagnostic methods for endometriosis using AI and imaging data.
- Women aged 18–45 in Australia with prior pelvic MRI or TVUS scans who want to contribute to endometriosis research.
- Gynecologists and radiologists exploring AI-assisted imaging tools to complement or replace surgical diagnosis.
- Healthcare institutions and policymakers evaluating AI applications in women's reproductive health diagnostics.
- Academic and clinical teams publishing research on AI-driven improvements in endometriosis detection and patient outcomes.
Pros
- Addresses a Critical Healthcare Gap: Targets the well-documented problem of delayed endometriosis diagnosis, which can average 7–10 years in many patients.
- Non-Invasive Alternative: Offers a potential path to diagnosis without surgery, reducing patient risk, discomfort, and healthcare costs.
- Strong Institutional Backing: Supported by reputable government bodies and medical organizations, lending credibility and resources to the research.
Cons
- Limited to Research Context: Currently operates as a clinical study rather than a commercially available diagnostic tool, limiting broad accessibility.
- Geographic Restriction: Primarily targets participants in Australia, limiting global participation and applicability at this stage.
- Narrow Eligibility Criteria: Participation is restricted to females aged 18–45 meeting specific medical criteria, excluding a large portion of potential participants.
Frequently Asked Questions
What is IMAGENDO®?
IMAGENDO® is an Australian medical research study that uses artificial intelligence to analyze pelvic MRI and ultrasound images to diagnose endometriosis non-invasively.
Who can participate in the IMAGENDO® study?
The study is open to females aged 18–45. Stage One is for those who have had a pelvic MRI or transvaginal ultrasound, and Stage Three is for those planning pelvic surgery within six months.
How does IMAGENDO® use artificial intelligence?
IMAGENDO® applies AI algorithms to medical imaging data — specifically MRI and TVUS scans — to identify patterns associated with endometriosis, enabling diagnosis without surgical intervention.
Is IMAGENDO® a free service?
Yes, participation in the IMAGENDO® study is free. The research is funded by the Australian Government and several medical organizations.
What is the goal of the IMAGENDO® study?
The goal is to develop and validate an AI-based imaging tool that can reliably detect endometriosis non-invasively, significantly reducing the current diagnostic delay experienced by patients.
